Find Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) in Phase I Clinical Development

Lead Product(s): MET409

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2020

Details:

Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409

Lead Product(s): HM15211

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2020

Details:

HM12525A is the world's first anti-obesity treatment that works as a once-weekly injection. Its efficacy was proven to be higher than existing daily-injection obesity treatment in Phase 2 trials.

Lead Product(s): TERN-201

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Data presented at nash-tag conference 2020 showed over 90% reduction in plasma SSAO activity after single dose administrations of TERN-201.

Lead Product(s): CRV431

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

The presentation will provide further data from four nonclinical studies demonstrating that CRV431 decreases liver fibrosis in animal and human tissue experimental models.